



28 January 2025

Immupharma PLC

("Immupharma" or the "Company")

Response to Share Price Movement

Immupharma PLC (LSE:IMM), the specialist drug discovery and development company, notes the recent movements in its share price.

As announced on 9 January 2025, the Company has made innovative groundbreaking advancements in its preclinical research program focused on P140 and the pathogenesis of autoimmune diseases. This new discovery, conducted by the Company's R&D subsidiary Immupharma Biotech, has yielded data that provides novel insights into autoimmune disease mechanisms. Through this research, the Company is making a significant step towards personalised medicine in SLE and other autoimmune diseases.

(Link: <https://www.immupharma.co.uk/news/>)

The Immupharma team also attended the JP Morgan and Biotech Showcase healthcare conferences earlier this month.

Attending both meetings gave the Immupharma team the opportunity to continue positive discussions with a number of global BioPharma companies, that have already expressed an interest in P140 and its unique approach to treating autoimmune diseases.

Immupharma is not aware of any further material commercial or operational reason for the significant share price movements, however, the Company will continue to update the market on developments, both commercially and scientifically, when appropriate, over the next period.

End

For further information please contact:

Immupharma PLC (www.immupharma.co.uk)

+44 (0) 207 206 2650

Tim McCarthy, Chief Executive Officer

Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413496

SPARK Advisory Partners Limited (NOMAD)

+44 (0) 203 368 3550

Neil Baldwin

Stanford Capital Partners (Joint Broker)

+44 (0) 20 3650 3650

Patrick Claridge, Bob Pountney

SI Capital (Joint Broker)

+44 (0) 1483 413500

Nick Emerson

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140, is a unique non-immunosuppressive peptide for the treatment of SLE (Systemic Lupus Erythematosus) and CIDP (Chronic Idiopathic Demyelinating Polyneuropathy) and preclinical models suggest therapeutic activity for many other autoimmune diseases.

For additional information about ImmuPharma please visit www.immupharma.co.uk

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

SPMBDGDBLUDDGUI